SCHEMBL1032998

SCHEMBL1032998

OC(COCCCl)[C@H](Cl)I

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28299084 0.75
SCHEMBL17769312 0.72 HSD17B10 (0.40)
SCHEMBL3485216 0.69 HSD17B10 (0.37)
SCHEMBL1332926 0.69
SCHEMBL1332928 0.69
SCHEMBL30558029 0.69
SCHEMBL8610305 0.66
SCHEMBL17769278 0.65
SCHEMBL8431231 0.64 HSD17B10 (0.33)
SCHEMBL3485650 0.62 HSD17B10 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011008931-A2 ARYLPYRIMIDINE COMPOUNDS AND COMBINATION THERAPY COMPRISING SAME FOR TREATING CYSTIC FIBROSIS &amp; RELATED DISORDERS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2011-01-20 WO disclosed